About Us

At Acumen, we are singularly focused on the development of targeted therapies for Alzheimer’s disease, a condition that has remained untreatable for far too long.

Focus on Alzheimer’s

We are at a breakthrough moment for Alzheimer’s disease research and drug development.

Acumen is leveraging decades of learnings to deliver treatments FOR the benefit of everyone impacted by this devastating disease.

Our Vision

With passion, expertise, and perseverance, we are forging a path towards innovative treatments that preserve quality time for all people impacted by Alzheimer’s and other neurodegenerative diseases.

Our History

Our founders pioneered seminal discoveries and methods to understand the role of toxic soluble amyloid beta oligomers (AβOs) in synaptic dysfunction and neurodegeneration. Today, Acumen’s leaders are leveraging critical insights to advance the company and sabirnetug (ACU193) in the clinic and beyond.

 
1234567891011

1996

Acumen acquires exclusive licenses to the Aβ-derived diffusible ligands (ADDLs) intellectual property of Northwestern University and University of Southern California.

2004

Acumen and Merck & Co. enter exclusive license and research collaboration

2012

Acumen receives ACU193 program exclusivity

2017

National Institute of Aging awards $3.6 million U01 grant for development of ACU193

2018

Former Lilly Alzheimer’s disease development team engaged,

Acumen closes on a $15 million Series A-1 round

2020

Acumen closes on a $75 million Series B round

2021

A first-in-human, Phase 1 clinical trial (INTERCEPT-AD) of sabirnetug (ACU193) in early Alzheimer’s disease patients initiated. Acumen becomes a publicly traded company (NASDAQ:ABOS) and hires first 14 employees

2022

Acumen doubles the size of the organization to 34 employees and advances the INTERCEPT-AD trial, continues enrollment with projected top-line results in 2023

2023

Acumen reports positive results from Phase 1 INTERCEPT-AD Trial presenting data at both AAIC and CTAD

2024

The Phase 2 clinical trial (ALTITUDE-AD) of sabirnetug (ACU193) in early Alzheimer’s disease patients initiated.

2025

Announced topline results from Phase 1 study of subcutaneous formulation of sabirnetug and completed enrollment for Phase 2 ALTITUDE-AD study of IV sabirnetug.